- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT03914612
Testování přidání imunoterapeutického léku Pembrolizumabu k obvyklé chemoterapeutické léčbě (paklitaxel a karboplatina) ve stadiu III-IV nebo recidivující rakovině endometria
Randomizovaná, placebem kontrolovaná studie fáze III pembrolizumabu (MK-3475, NSC #776864) navíc k paklitaxelu a karboplatině pro měřitelné stadium III nebo IVA, stadium IVB nebo recidivující karcinom endometria
This phase III trial studies how well the combination of pembrolizumab, paclitaxel and carboplatin works compared with paclitaxel and carboplatin alone in treating patients with endometrial cancer that is stage III or IV, or has come back after a period of improvement (recurrent). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Paclitaxel and carboplatin are chemotherapy drugs used as part of the usual treatment approach for this type of cancer. This study aims to assess if adding immunotherapy to these drugs is better or worse than the usual approach for treatment of this cancer.
Přehled studie
Postavení
Podmínky
- Endometriální průhledný adenokarcinom
- Endometriální dediferencovaný karcinom
- Endometrioidní endometrioidní adenokarcinom
- Endometriální smíšený buněčný adenokarcinom
- Endometriální serózní adenokarcinom
- Endometriální nediferencovaný karcinom
- Recidivující endometriální adenokarcinom
- Recidivující karcinom endometria
- Recidivující endometriální adenokarcinom z jasných buněk
- Recidivující endometriální dediferencovaný karcinom
- Recidivující endometrioidní adenokarcinom endometria
- Recidivující endometriální smíšený buněčný adenokarcinom
- Recidivující serózní adenokarcinom endometria
- Recidivující endometriální nediferencovaný karcinom
- Stage III děložní karcinom nebo karcinosarkom AJCC V8
- Stage IV děložní karcinom nebo karcinosarkom AJCC V8
Detailní popis
PRIMARY OBJECTIVE:
I. To evaluate the efficacy of pembrolizumab (MK-3475) in combination with paclitaxel and carboplatin in patients with advanced stage (measurable stage III or IVA), stage IVB and recurrent endometrial cancer.
SECONDARY OBJECTIVES:
I. To determine the nature, frequency and degree of toxicity as assessed by Common Terminology Criteria for Adverse Events (CTCAE) for each treatment arm.
II. To evaluate blinded independent central review (BICR) assessed or investigator assessed objective response rate (ORR) as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by treatment arm and by mismatch repair (MMR) immunohistochemistry (IHC) status in patients who enter the study with measurable disease.
III. To evaluate BICR assessed or investigator assessed duration of response (DOR) by treatment arm and by MMR IHC status in patients who enter the study with measurable disease.
IV. To evaluate the effect of pembrolizumab (MK-3475) on overall survival (OS) in patients with mismatch repair protein proficient (pMMR) or mismatch repair deficiency (dMMR).
V. To determine whether the addition of pembrolizumab (MK-3475) to standard combination chemotherapy is associated with improved patient reported physical function as measured with the Patient-Reported Outcomes Measurement Information System (PROMIS)-physical function scale (short form), quality of life as measured with the Functional Assessment of Cancer Therapy (FACT) - Endometrial Trial Outcome Index (En TOI) and worsened fatigue as measured with the PROMIS-Fatigue scale (short form) in the pMMR patients.
VI. To determine concordance between institutional MMR IHC testing and centralized MMR IHC.
EXPLORATORY OBJECTIVES:
I. To explore the correlation between patient-reported physical function as measured with the PROMIS-physical function scale (short form) and quality of life as measure with the FACT-En TOI.
II. To explore whether the addition of pembrolizumab (MK-3475) to standard combination chemotherapy is associated with self-reported neurotoxicity as measured with the FACT/Gynecologic Oncology Group Neurotoxicity (GOG-Ntx) subscale (short) and the extent to which patients differ on their self-reported bother from side effects of cancer therapy in the pMMR patients.
III. To evaluate the efficacy of pembrolizumab (MK-3475) in combination with paclitaxel and carboplatin in patients with advanced stage (measurable stage III or IVA), stage IVB and recurrent endometrial cancer by Programmed Death Ligand 1 (PD-L1) IHC (positive versus [vs] negative).
IV. To assess the association between PD-L1 IHC (positive vs negative) and mismatch repair status (pMMR and dMMR).
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I:
COMBINATION PHASE: Patients receive placebo intravenously (IV) over 30 minutes on day 1 of each cycle, paclitaxel IV over 3 hours on day 1 of each cycle, and carboplatin IV over 30-60 minutes on day 1 of each cycle. Treatment repeats every 3 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with stable disease (SD) or partial response (PR) who still have measurable disease may continue treatment for up to a total 10 cycles (if deemed necessary by the treating physician) in the absence of disease progression or unacceptable toxicity.
MAINTENANCE PHASE: Patients receive placebo IV over 30 minutes on day 1 of each cycle. Treatment repeats every 6 weeks for up to 14 cycles in the absence of disease progression or unacceptable toxicity.
On February 6, 2023, all patient treatment assignments were unblinded. Patients randomized to Arm I will not receive additional placebo infusions.
ARM II:
COMBINATION PHASE: Patients receive pembrolizumab IV over 30 minutes on day 1 of each cycle, paclitaxel IV over 3 hours on day 1 of each cycle, and carboplatin IV over 30-60 minutes on day 1 of each cycle. Treatment repeats every 3 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with SD or PR who still have measurable disease may continue treatment for up to a total of 10 cycles (if deemed necessary by the treating physician) in the absence of disease progression or unacceptable toxicity.
MAINTENANCE PHASE: Patients receive pembrolizumab IV over 30 minutes on day 1 of each cycle. Treatment repeats every 6 weeks for up to 14 cycles in the absence of disease progression or unacceptable toxicity.
Patients undergo computed tomography (CT) scan throughout the study.
After completion of study treatment, patients are followed up every 3 months for 2 years and then every 6 months for 3 years.
Typ studie
Zápis (Aktuální)
Fáze
- Fáze 3
Kontakty a umístění
Studijní místa
-
-
-
Saitama, Japonsko, 350-1298
- Saitama Medical University International Medical Center
-
-
Ehime
-
Tōon, Ehime, Japonsko, 791-0295
- Ehime University Hospital
-
-
Hiroshima
-
Kure, Hiroshima, Japonsko, 737
- Kure Medical Center and Chugoku Cancer Center
-
-
Niigata
-
Niigata, Niigata, Japonsko, 951-8520
- Niigata University Medical and Dental Hospital
-
-
-
-
-
Daegu, Jižní Korea, 41404
- Kyungpook National University Chilgok Hospital
-
Seoul, Jižní Korea, 05505
- Asan Medical Center
-
Seoul, Jižní Korea, 06273
- Gangnam Severance Hospital
-
Seoul, Jižní Korea, 120-752
- Yonsei University Health System-Severance Hospital
-
Seoul, Jižní Korea, 139-706
- Korea Cancer Center Hospital
-
-
Daegu
-
Dalseo-gu, Daegu, Jižní Korea, 42601
- Keimyung University-Dongsan Medical Center
-
-
Gyeongsangnam-do
-
Seoul, Gyeongsangnam-do, Jižní Korea, 51353
- Samsung Changwon Hospital
-
-
Kyeonggi-do
-
Seongnam, Kyeonggi-do, Jižní Korea, 463-707
- Seoul National University Bundang Hospital
-
-
-
-
New Brunswick
-
Moncton, New Brunswick, Kanada, E1C 6Z8
- The Moncton Hospital
-
-
Ontario
-
Barrie, Ontario, Kanada, L4M 6M2
- Royal Victoria Regional Health Centre
-
Greater Sudbury, Ontario, Kanada, P3E 5J1
- Health Sciences North
-
Hamilton, Ontario, Kanada, L8V 5C2
- Juravinski Cancer Centre at Hamilton Health Sciences
-
Kingston, Ontario, Kanada, K7L 2V7
- Kingston Health Sciences Centre
-
London, Ontario, Kanada, N6A 4L6
- London Regional Cancer Program
-
Oshawa, Ontario, Kanada, L1G 2B9
- Lakeridge Health Oshawa
-
Sault Ste. Marie, Ontario, Kanada, P6B 0A8
- Algoma District Cancer Program Sault Area Hospital
-
Toronto, Ontario, Kanada, M5G 2M9
- University Health Network-Princess Margaret Hospital
-
Toronto, Ontario, Kanada, M4N 3M5
- Odette Cancer Centre- Sunnybrook Health Sciences Centre
-
-
Quebec
-
Laval, Quebec, Kanada, H7M 3L9
- Hopital de la Cite-de-la-Sante
-
Montreal, Quebec, Kanada, H2X 3E4
- CHUM - Centre Hospitalier de l'Universite de Montreal
-
-
Saskatchewan
-
Regina, Saskatchewan, Kanada, S4T 7T1
- Allan Blair Cancer Centre
-
Saskatoon, Saskatchewan, Kanada, S7N 4H4
- Saskatoon Cancer Centre
-
-
-
-
-
San Juan, Portoriko, 00927
- Centro Comprensivo de Cancer de UPR
-
-
-
-
Alabama
-
Birmingham, Alabama, Spojené státy, 35233
- University of Alabama at Birmingham Cancer Center
-
-
Alaska
-
Anchorage, Alaska, Spojené státy, 99508
- Alaska Women's Cancer Care
-
-
Arizona
-
Goodyear, Arizona, Spojené státy, 85338
- CTCA at Western Regional Medical Center
-
-
Arkansas
-
Jonesboro, Arkansas, Spojené státy, 72401
- NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro
-
Little Rock, Arkansas, Spojené státy, 72205
- University of Arkansas for Medical Sciences
-
-
California
-
Baldwin Park, California, Spojené státy, 91706
- Kaiser Permanente-Baldwin Park
-
Bellflower, California, Spojené státy, 90706
- Kaiser Permanente-Bellflower
-
Berkeley, California, Spojené státy, 94704
- Alta Bates Summit Medical Center-Herrick Campus
-
Clovis, California, Spojené státy, 93611
- Community Cancer Institute
-
Duarte, California, Spojené státy, 91010
- City of Hope Comprehensive Cancer Center
-
Harbor City, California, Spojené státy, 90710
- Kaiser Permanente South Bay
-
Irvine, California, Spojené státy, 92618
- Kaiser Permanente-Irvine
-
La Jolla, California, Spojené státy, 92093
- UC San Diego Moores Cancer Center
-
Lancaster, California, Spojené státy, 93534
- City of Hope Antelope Valley
-
Los Angeles, California, Spojené státy, 90033
- USC / Norris Comprehensive Cancer Center
-
Los Angeles, California, Spojené státy, 90048
- Cedars-Sinai Medical Center
-
Los Angeles, California, Spojené státy, 90095
- UCLA / Jonsson Comprehensive Cancer Center
-
Los Angeles, California, Spojené státy, 90027
- Kaiser Permanente Los Angeles Medical Center
-
Los Angeles, California, Spojené státy, 90033
- Los Angeles General Medical Center
-
Mountain View, California, Spojené státy, 94040
- Palo Alto Medical Foundation-Gynecologic Oncology
-
Oakland, California, Spojené státy, 94611
- Kaiser Permanente-Oakland
-
Orange, California, Spojené státy, 92868
- UC Irvine Health/Chao Family Comprehensive Cancer Center
-
Orange, California, Spojené státy, 92868
- Saint Joseph Hospital - Orange
-
Rancho Mirage, California, Spojené státy, 92270
- Eisenhower Medical Center
-
Redding, California, Spojené státy, 96001
- Mercy Regional Cancer Center
-
Redding, California, Spojené státy, 96002
- Mercy Oncology Center
-
Riverside, California, Spojené státy, 92505
- Kaiser Permanente-Riverside
-
Roseville, California, Spojené státy, 95661
- Kaiser Permanente-Roseville
-
Sacramento, California, Spojené státy, 95817
- University of California Davis Comprehensive Cancer Center
-
Sacramento, California, Spojené státy, 95814
- Kaiser Permanente Downtown Commons
-
Sacramento, California, Spojené státy, 95816
- Mercy Cancer Center - Sacramento
-
San Diego, California, Spojené státy, 92120
- Kaiser Permanente-San Diego Zion
-
San Diego, California, Spojené státy, 92134
- Naval Medical Center -San Diego
-
San Francisco, California, Spojené státy, 94115
- Kaiser Permanente-San Francisco
-
San Francisco, California, Spojené státy, 94158
- UCSF Medical Center-Mission Bay
-
San Francisco, California, Spojené státy, 94115
- California Pacific Medical Center-Pacific Campus
-
San Francisco, California, Spojené státy, 94110
- Zuckerberg San Francisco General Hospital
-
San Jose, California, Spojené státy, 95119
- Kaiser Permanente-Santa Teresa-San Jose
-
San Leandro, California, Spojené státy, 94577
- Kaiser Permanente San Leandro
-
San Marcos, California, Spojené státy, 92078
- Kaiser Permanente-San Marcos
-
Santa Clara, California, Spojené státy, 95051
- Kaiser Permanente Medical Center - Santa Clara
-
South Pasadena, California, Spojené státy, 91030
- City of Hope South Pasadena
-
South San Francisco, California, Spojené státy, 94080
- Kaiser Permanente-South San Francisco
-
Sunnyvale, California, Spojené státy, 94086
- Palo Alto Medical Foundation-Sunnyvale
-
Upland, California, Spojené státy, 91786
- City of Hope Upland
-
Vallejo, California, Spojené státy, 94589
- Kaiser Permanente-Vallejo
-
Walnut Creek, California, Spojené státy, 94596
- Kaiser Permanente-Walnut Creek
-
Walnut Creek, California, Spojené státy, 94598
- John Muir Medical Center-Walnut Creek
-
-
Colorado
-
Colorado Springs, Colorado, Spojené státy, 80907
- Penrose-Saint Francis Healthcare
-
Colorado Springs, Colorado, Spojené státy, 80909
- UCHealth Memorial Hospital Central
-
Colorado Springs, Colorado, Spojené státy, 80920
- Memorial Hospital North
-
Fort Collins, Colorado, Spojené státy, 80524
- Poudre Valley Hospital
-
Fort Collins, Colorado, Spojené státy, 80528
- Cancer Care and Hematology-Fort Collins
-
Greeley, Colorado, Spojené státy, 80631
- UCHealth Greeley Hospital
-
Greeley, Colorado, Spojené státy, 80631
- Banner North Colorado Medical Center
-
Loveland, Colorado, Spojené státy, 80538
- Medical Center of the Rockies
-
Loveland, Colorado, Spojené státy, 80539
- Banner North Colorado Medical Center - Loveland Campus
-
-
Connecticut
-
Danbury, Connecticut, Spojené státy, 06810
- Danbury Hospital
-
Guilford, Connecticut, Spojené státy, 06437
- Smilow Cancer Hospital Care Center - Guilford
-
Hartford, Connecticut, Spojené státy, 06105
- Smilow Cancer Hospital Care Center at Saint Francis
-
Hartford, Connecticut, Spojené státy, 06102
- Hartford Hospital
-
New Britain, Connecticut, Spojené státy, 06050
- The Hospital of Central Connecticut
-
New Haven, Connecticut, Spojené státy, 06520
- Yale University
-
North Haven, Connecticut, Spojené státy, 06473
- Yale-New Haven Hospital North Haven Medical Center
-
Norwalk, Connecticut, Spojené státy, 06856
- Norwalk Hospital
-
Stamford, Connecticut, Spojené státy, 06904
- Stamford Hospital/Bennett Cancer Center
-
Torrington, Connecticut, Spojené státy, 06790
- Smilow Cancer Hospital-Torrington Care Center
-
Trumbull, Connecticut, Spojené státy, 06611
- Smilow Cancer Hospital Care Center-Trumbull
-
Waterbury, Connecticut, Spojené státy, 06708
- Smilow Cancer Hospital-Waterbury Care Center
-
Waterford, Connecticut, Spojené státy, 06385
- Smilow Cancer Hospital Care Center - Waterford
-
-
Delaware
-
Newark, Delaware, Spojené státy, 19713
- Helen F Graham Cancer Center
-
-
District of Columbia
-
Washington D.C., District of Columbia, Spojené státy, 20010
- MedStar Washington Hospital Center
-
Washington D.C., District of Columbia, Spojené státy, 20016
- Sibley Memorial Hospital
-
-
Florida
-
Bradenton, Florida, Spojené státy, 34205
- Florida Cancer Specialists - Bradenton Cancer Center
-
Sarasota, Florida, Spojené státy, 34239
- Sarasota Memorial Hospital
-
Sarasota, Florida, Spojené státy, 34232
- Florida Cancer Specialists - Sarasota
-
Sarasota, Florida, Spojené státy, 34239
- Florida Cancer Specialists - Sarasota Downtown
-
Venice, Florida, Spojené státy, 34285
- Florida Cancer Specialists - Venice Island
-
Venice, Florida, Spojené státy, 34275
- Florida Cancer Specialists - Venice Pinebrook
-
-
Georgia
-
Atlanta, Georgia, Spojené státy, 30308
- Emory University Hospital Midtown
-
Atlanta, Georgia, Spojené státy, 30322
- Emory University Hospital/Winship Cancer Institute
-
Atlanta, Georgia, Spojené státy, 30342
- Emory Saint Joseph's Hospital
-
Atlanta, Georgia, Spojené státy, 30303
- Grady Health System
-
Atlanta, Georgia, Spojené státy, 30342
- Northside Hospital
-
Austell, Georgia, Spojené státy, 30106
- WellStar Cobb Hospital
-
Fayetteville, Georgia, Spojené státy, 30214
- Piedmont Fayette Hospital
-
Gainesville, Georgia, Spojené státy, 30501
- Northeast Georgia Medical Center-Gainesville
-
Marietta, Georgia, Spojené státy, 30060
- Wellstar Kennestone Hospital
-
Marietta, Georgia, Spojené státy, 30060
- WellStar Health System Inc
-
Newnan, Georgia, Spojené státy, 30265
- CTCA at Southeastern Regional Medical Center
-
Roswell, Georgia, Spojené státy, 30076
- WellStar North Fulton Hospital
-
Savannah, Georgia, Spojené státy, 31405
- Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
-
Savannah, Georgia, Spojené státy, 31404
- Memorial Health University Medical Center
-
Smyrna, Georgia, Spojené státy, 30080
- WellStar Vinings Health Park
-
-
Hawaii
-
Honolulu, Hawaii, Spojené státy, 96813
- Queen's Medical Center
-
Honolulu, Hawaii, Spojené státy, 96826
- Kapiolani Medical Center for Women and Children
-
-
Idaho
-
Boise, Idaho, Spojené státy, 83706
- Saint Alphonsus Cancer Care Center-Boise
-
Boise, Idaho, Spojené státy, 83712
- Saint Luke's Cancer Institute - Boise
-
Caldwell, Idaho, Spojené státy, 83605
- Saint Alphonsus Cancer Care Center-Caldwell
-
Fruitland, Idaho, Spojené státy, 83619
- Saint Luke's Cancer Institute - Fruitland
-
Meridian, Idaho, Spojené státy, 83642
- Saint Luke's Cancer Institute - Meridian
-
Nampa, Idaho, Spojené státy, 83687
- Saint Alphonsus Cancer Care Center-Nampa
-
Nampa, Idaho, Spojené státy, 83687
- Saint Luke's Cancer Institute - Nampa
-
Twin Falls, Idaho, Spojené státy, 83301
- Saint Luke's Cancer Institute - Twin Falls
-
-
Illinois
-
Chicago, Illinois, Spojené státy, 60611
- Northwestern University
-
Chicago, Illinois, Spojené státy, 60637
- University of Chicago Comprehensive Cancer Center
-
Chicago, Illinois, Spojené státy, 60612
- University of Illinois
-
Chicago, Illinois, Spojené státy, 60612
- Rush MD Anderson Cancer Center
-
Danville, Illinois, Spojené státy, 61832
- Carle at The Riverfront
-
Decatur, Illinois, Spojené státy, 62526
- Cancer Care Specialists of Illinois - Decatur
-
Effingham, Illinois, Spojené státy, 62401
- Crossroads Cancer Center
-
Evanston, Illinois, Spojené státy, 60201
- NorthShore University HealthSystem-Evanston Hospital
-
Geneva, Illinois, Spojené státy, 60134
- Northwestern Medicine Cancer Center Delnor
-
Glenview, Illinois, Spojené státy, 60026
- NorthShore University HealthSystem-Glenbrook Hospital
-
Harvey, Illinois, Spojené státy, 60426
- Ingalls Memorial Hospital
-
Highland Park, Illinois, Spojené státy, 60035
- NorthShore University HealthSystem-Highland Park Hospital
-
Mattoon, Illinois, Spojené státy, 61938
- Carle Physician Group-Mattoon/Charleston
-
Maywood, Illinois, Spojené státy, 60153
- Loyola University Medical Center
-
New Lenox, Illinois, Spojené státy, 60451
- UC Comprehensive Cancer Center at Silver Cross
-
O'Fallon, Illinois, Spojené státy, 62269
- Cancer Care Center of O'Fallon
-
Orland Park, Illinois, Spojené státy, 60462
- University of Chicago Medicine-Orland Park
-
Springfield, Illinois, Spojené státy, 62702
- Springfield Clinic
-
Urbana, Illinois, Spojené státy, 61801
- Carle Cancer Center
-
Warrenville, Illinois, Spojené státy, 60555
- Northwestern Medicine Cancer Center Warrenville
-
Zion, Illinois, Spojené státy, 60099
- Midwestern Regional Medical Center
-
-
Indiana
-
Crown Point, Indiana, Spojené státy, 46307
- Northwest Cancer Center - Crown Point
-
Dyer, Indiana, Spojené státy, 46311
- Northwest Oncology LLC
-
Hobart, Indiana, Spojené státy, 46342
- Northwest Cancer Center - Hobart
-
Hobart, Indiana, Spojené státy, 46342
- Saint Mary Medical Center
-
Indianapolis, Indiana, Spojené státy, 46237
- Franciscan Health Indianapolis
-
Indianapolis, Indiana, Spojené státy, 46202
- Indiana University/Melvin and Bren Simon Cancer Center
-
Indianapolis, Indiana, Spojené státy, 46219
- Community Cancer Center East
-
Indianapolis, Indiana, Spojené státy, 46227
- Community Cancer Center South
-
Indianapolis, Indiana, Spojené státy, 46256
- Community Cancer Center North
-
Indianapolis, Indiana, Spojené státy, 46260
- Ascension Saint Vincent Indianapolis Hospital
-
Indianapolis, Indiana, Spojené státy, 46312
- Saint Catherine Hospital
-
Mooresville, Indiana, Spojené státy, 46158
- Franciscan Health Mooresville
-
Munster, Indiana, Spojené státy, 46321
- The Community Hospital
-
Munster, Indiana, Spojené státy, 46321
- Women's Diagnostic Center - Munster
-
Valparaiso, Indiana, Spojené státy, 46383
- Northwest Cancer Center - Valparaiso
-
-
Iowa
-
Iowa City, Iowa, Spojené státy, 52242
- University of Iowa/Holden Comprehensive Cancer Center
-
-
Kansas
-
Fairway, Kansas, Spojené státy, 66205
- University of Kansas Clinical Research Center
-
Kansas City, Kansas, Spojené státy, 66160
- University of Kansas Cancer Center
-
Overland Park, Kansas, Spojené státy, 66211
- University of Kansas Hospital-Indian Creek Campus
-
Westwood, Kansas, Spojené státy, 66205
- University of Kansas Hospital-Westwood Cancer Center
-
-
Kentucky
-
Edgewood, Kentucky, Spojené státy, 41017
- Saint Elizabeth Healthcare Edgewood
-
-
Louisiana
-
Baton Rouge, Louisiana, Spojené státy, 70805
- LSU Health Baton Rouge-North Clinic
-
Baton Rouge, Louisiana, Spojené státy, 70808
- Our Lady of The Lake
-
Baton Rouge, Louisiana, Spojené státy, 70817
- Woman's Hospital
-
Baton Rouge, Louisiana, Spojené státy, 70817
- Our Lady of the Lake Medical Oncology
-
Baton Rouge, Louisiana, Spojené státy, 70808
- Our Lady of the Lake Physician Group
-
Metairie, Louisiana, Spojené státy, 70006
- East Jefferson General Hospital
-
New Orleans, Louisiana, Spojené státy, 70121
- Ochsner Medical Center Jefferson
-
New Orleans, Louisiana, Spojené státy, 70112
- University Medical Center New Orleans
-
New Orleans, Louisiana, Spojené státy, 70115
- Ochsner Baptist Medical Center
-
-
Maine
-
Augusta, Maine, Spojené státy, 04330
- Harold Alfond Center for Cancer Care
-
Belfast, Maine, Spojené státy, 04915
- MaineHealth Waldo Hospital
-
Biddeford, Maine, Spojené státy, 04005
- MaineHealth Maine Medical Center - Biddeford
-
Brewer, Maine, Spojené státy, 04412
- Lafayette Family Cancer Center-EMMC
-
Rockport, Maine, Spojené státy, 04856
- Penobscot Bay Medical Center
-
Sanford, Maine, Spojené státy, 04073
- MaineHealth Cancer Care and IV Therapy - Sanford
-
Scarborough, Maine, Spojené státy, 04074
- MaineHealth Maine Medical Center- Scarborough
-
-
Maryland
-
Annapolis, Maryland, Spojené státy, 21401
- Luminis Health Anne Arundel Medical Center
-
Baltimore, Maryland, Spojené státy, 21237
- MedStar Franklin Square Medical Center/Weinberg Cancer Institute
-
Baltimore, Maryland, Spojené státy, 21287
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
Baltimore, Maryland, Spojené státy, 21215
- Sinai Hospital of Baltimore
-
Baltimore, Maryland, Spojené státy, 21204
- Greater Baltimore Medical Center
-
Baltimore, Maryland, Spojené státy, 21201
- University of Maryland/Greenebaum Cancer Center
-
Baltimore, Maryland, Spojené státy, 21229
- Saint Agnes Hospital
-
Bel Air, Maryland, Spojené státy, 21014
- UM Upper Chesapeake Medical Center
-
Bethesda, Maryland, Spojené státy, 20889-5600
- Walter Reed National Military Medical Center
-
Easton, Maryland, Spojené státy, 21601
- University of Maryland Shore Medical Center at Easton
-
-
Massachusetts
-
Burlington, Massachusetts, Spojené státy, 01805
- Lahey Clinic
-
Lowell, Massachusetts, Spojené státy, 01854
- Lowell General Hospital
-
Springfield, Massachusetts, Spojené státy, 01199
- Baystate Medical Center
-
Winchester, Massachusetts, Spojené státy, 01890
- Beth Israel Deaconess Medical Center/Winchester Center for Cancer Care
-
Worcester, Massachusetts, Spojené státy, 01605
- UMass Memorial Medical Center - Memorial Division
-
-
Michigan
-
Ann Arbor, Michigan, Spojené státy, 48109
- University of Michigan Rogel Cancer Center
-
Ann Arbor, Michigan, Spojené státy, 48106
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
-
Flint, Michigan, Spojené státy, 48503
- Genesee Hematology Oncology PC
-
Flint, Michigan, Spojené státy, 48503
- Genesys Hurley Cancer Institute
-
Flint, Michigan, Spojené státy, 48503
- Cancer Hematology Centers - Flint
-
Grand Rapids, Michigan, Spojené státy, 49503
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital
-
Kalamazoo, Michigan, Spojené státy, 49007
- West Michigan Cancer Center
-
Kalamazoo, Michigan, Spojené státy, 49007
- Bronson Methodist Hospital
-
Lansing, Michigan, Spojené státy, 48912
- University of Michigan Health - Sparrow Lansing
-
Traverse City, Michigan, Spojené státy, 49684
- Munson Medical Center
-
-
Minnesota
-
Bemidji, Minnesota, Spojené státy, 56601
- Sanford Joe Lueken Cancer Center
-
Duluth, Minnesota, Spojené státy, 55805
- Essentia Health Cancer Center
-
Rochester, Minnesota, Spojené státy, 55905
- Mayo Clinic in Rochester
-
-
Mississippi
-
Jackson, Mississippi, Spojené státy, 39216
- University of Mississippi Medical Center
-
Jackson, Mississippi, Spojené státy, 39202
- Mississippi Baptist Medical Center
-
-
Missouri
-
Kansas City, Missouri, Spojené státy, 64111
- Saint Luke's Hospital of Kansas City
-
Springfield, Missouri, Spojené státy, 65804
- Mercy Hospital Springfield
-
St Louis, Missouri, Spojené státy, 63110
- Washington University School of Medicine
-
St Louis, Missouri, Spojené státy, 63141
- Mercy Hospital Saint Louis
-
-
Montana
-
Anaconda, Montana, Spojené státy, 59711
- Community Hospital of Anaconda
-
Billings, Montana, Spojené státy, 59101
- Billings Clinic Cancer Center
-
-
Nebraska
-
Grand Island, Nebraska, Spojené státy, 68803
- Nebraska Cancer Specialists/Oncology Hematology West PC
-
Omaha, Nebraska, Spojené státy, 68114
- Nebraska Methodist Hospital
-
Omaha, Nebraska, Spojené státy, 68198
- University of Nebraska Medical Center
-
-
New Hampshire
-
Lebanon, New Hampshire, Spojené státy, 03756
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
-
-
New Jersey
-
Basking Ridge, New Jersey, Spojené státy, 07920
- Memorial Sloan Kettering Basking Ridge
-
Camden, New Jersey, Spojené státy, 08103
- Cooper Hospital University Medical Center
-
Lakewood, New Jersey, Spojené státy, 08701
- Monmouth Medical Center Southern Campus
-
Livingston, New Jersey, Spojené státy, 07039
- Cooperman Barnabas Medical Center
-
Long Branch, New Jersey, Spojené státy, 07740
- Monmouth Medical Center
-
Middletown, New Jersey, Spojené státy, 07748
- Memorial Sloan Kettering Monmouth
-
Montvale, New Jersey, Spojené státy, 07645
- Memorial Sloan Kettering Bergen
-
Neptune City, New Jersey, Spojené státy, 07753
- Jersey Shore Medical Center
-
New Brunswick, New Jersey, Spojené státy, 08903
- Rutgers Cancer Institute of New Jersey
-
Paramus, New Jersey, Spojené státy, 07652
- The Valley Hospital - Luckow Pavilion
-
Ridgewood, New Jersey, Spojené státy, 07450
- Neurosurgeons of New Jersey-Ridgewood
-
Ridgewood, New Jersey, Spojené státy, 07450
- Valley Health System Ridgewood Campus
-
Somerville, New Jersey, Spojené státy, 08876
- Robert Wood Johnson University Hospital Somerset
-
Toms River, New Jersey, Spojené státy, 08755
- Community Medical Center
-
Voorhees Township, New Jersey, Spojené státy, 08043
- MD Anderson Cancer Center at Cooper-Voorhees
-
Wayne, New Jersey, Spojené státy, 07470
- Valley Medical Group - Wayne Multispecialty Practice
-
Westwood, New Jersey, Spojené státy, 07675
- Valley Health System-Hematology/Oncology
-
-
New Mexico
-
Albuquerque, New Mexico, Spojené státy, 87106
- Southwest Gynecologic Oncology Associates Inc
-
Albuquerque, New Mexico, Spojené státy, 87106
- University of New Mexico Cancer Center
-
-
New York
-
Bay Shore, New York, Spojené státy, 11706
- Northwell Health Imbert Cancer Center
-
Brightwaters, New York, Spojené státy, 11718
- Island Gynecologic Oncology
-
Brooklyn, New York, Spojené státy, 11215
- New York-Presbyterian/Brooklyn Methodist Hospital
-
Buffalo, New York, Spojené státy, 14263
- Roswell Park Cancer Institute
-
Commack, New York, Spojené státy, 11725
- Memorial Sloan Kettering Commack
-
Flushing, New York, Spojené státy, 11355
- The New York Hospital Medical Center of Queens
-
Harrison, New York, Spojené státy, 10604
- Memorial Sloan Kettering Westchester
-
Lake Success, New York, Spojené státy, 11042
- Northwell Health/Center for Advanced Medicine
-
Mineola, New York, Spojené státy, 11501
- NYU Langone Hospital - Long Island
-
New Hyde Park, New York, Spojené státy, 11040
- Long Island Jewish Medical Center
-
New York, New York, Spojené státy, 10065
- Memorial Sloan Kettering Cancer Center
-
New York, New York, Spojené státy, 10029
- Mount Sinai Hospital
-
New York, New York, Spojené státy, 10032
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
-
New York, New York, Spojené státy, 10065
- NYP/Weill Cornell Medical Center
-
New York, New York, Spojené státy, 10011
- Mount Sinai Chelsea
-
New York, New York, Spojené státy, 10016
- Laura and Isaac Perlmutter Cancer Center at NYU Langone
-
Rochester, New York, Spojené státy, 14642
- University of Rochester
-
Rochester, New York, Spojené státy, 14620
- Highland Hospital
-
Staten Island, New York, Spojené státy, 10305
- Staten Island University Hospital
-
Stony Brook, New York, Spojené státy, 11794
- Stony Brook University Medical Center
-
Syracuse, New York, Spojené státy, 13210
- State University of New York Upstate Medical University
-
The Bronx, New York, Spojené státy, 10461
- Montefiore Medical Center-Einstein Campus
-
The Bronx, New York, Spojené státy, 10467
- Montefiore Medical Center - Moses Campus
-
Uniondale, New York, Spojené státy, 11553
- Memorial Sloan Kettering Nassau
-
Valhalla, New York, Spojené státy, 10595
- Westchester Medical Center
-
-
North Carolina
-
Chapel Hill, North Carolina, Spojené státy, 27599
- UNC Lineberger Comprehensive Cancer Center
-
Charlotte, North Carolina, Spojené státy, 28203
- Carolinas Medical Center/Levine Cancer Institute
-
Clinton, North Carolina, Spojené státy, 28328
- Southeastern Medical Oncology Center-Clinton
-
Concord, North Carolina, Spojené státy, 28025
- Atrium Health Cabarrus/LCI-Concord
-
Goldsboro, North Carolina, Spojené státy, 27534
- Southeastern Medical Oncology Center-Goldsboro
-
Hendersonville, North Carolina, Spojené státy, 28791
- Margaret R Pardee Memorial Hospital
-
Jacksonville, North Carolina, Spojené státy, 28546
- Southeastern Medical Oncology Center-Jacksonville
-
Wilmington, North Carolina, Spojené státy, 28401
- Novant Health New Hanover Regional Medical Center
-
Winston-Salem, North Carolina, Spojené státy, 27157
- Wake Forest University Health Sciences
-
-
North Dakota
-
Bismarck, North Dakota, Spojené státy, 58501
- Sanford Bismarck Medical Center
-
Fargo, North Dakota, Spojené státy, 58122
- Sanford Roger Maris Cancer Center
-
Fargo, North Dakota, Spojené státy, 58122
- Sanford Broadway Medical Center
-
-
Ohio
-
Akron, Ohio, Spojené státy, 44304
- Summa Health System - Akron Campus
-
Beachwood, Ohio, Spojené státy, 44122
- UHHS-Chagrin Highlands Medical Center
-
Canton, Ohio, Spojené státy, 44710
- Aultman Health Foundation
-
Centerville, Ohio, Spojené státy, 45459
- Miami Valley Hospital South
-
Chardon, Ohio, Spojené státy, 44024
- Geauga Hospital
-
Cincinnati, Ohio, Spojené státy, 45219
- University of Cincinnati Cancer Center-UC Medical Center
-
Cincinnati, Ohio, Spojené státy, 45220
- Good Samaritan Hospital - Cincinnati
-
Cleveland, Ohio, Spojené státy, 44106
- Case Western Reserve University
-
Cleveland, Ohio, Spojené státy, 44109
- MetroHealth Medical Center
-
Cleveland, Ohio, Spojené státy, 44195
- Cleveland Clinic Foundation
-
Cleveland, Ohio, Spojené státy, 44111
- Cleveland Clinic Cancer Center/Fairview Hospital
-
Columbus, Ohio, Spojené státy, 43214
- Riverside Methodist Hospital
-
Columbus, Ohio, Spojené státy, 43210
- Ohio State University Comprehensive Cancer Center
-
Columbus, Ohio, Spojené státy, 43219
- The Mark H Zangmeister Center
-
Mayfield Heights, Ohio, Spojené státy, 44124
- Hillcrest Hospital Cancer Center
-
Mentor, Ohio, Spojené státy, 44060
- UH Seidman Cancer Center at Lake Health Mentor Campus
-
Sylvania, Ohio, Spojené státy, 43560
- ProMedica Flower Hospital
-
West Chester, Ohio, Spojené státy, 45069
- University of Cincinnati Cancer Center-West Chester
-
Westlake, Ohio, Spojené státy, 44145
- UH Seidman Cancer Center at Saint John Medical Center
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Spojené státy, 73104
- University of Oklahoma Health Sciences Center
-
Tulsa, Oklahoma, Spojené státy, 74146
- Oklahoma Cancer Specialists and Research Institute-Tulsa
-
-
Oregon
-
Bend, Oregon, Spojené státy, 97701
- Saint Charles Health System
-
Ontario, Oregon, Spojené státy, 97914
- Saint Alphonsus Cancer Care Center-Ontario
-
Portland, Oregon, Spojené státy, 97210
- Legacy Good Samaritan Hospital and Medical Center
-
Portland, Oregon, Spojené státy, 97213
- Providence Portland Medical Center
-
Portland, Oregon, Spojené státy, 97225
- Providence Saint Vincent Medical Center
-
Tualatin, Oregon, Spojené státy, 97062
- Legacy Meridian Park Hospital
-
-
Pennsylvania
-
Allentown, Pennsylvania, Spojené státy, 18103
- Lehigh Valley Hospital-Cedar Crest
-
Bethlehem, Pennsylvania, Spojené státy, 18017
- Lehigh Valley Hospital - Muhlenberg
-
Danville, Pennsylvania, Spojené státy, 17822
- Geisinger Medical Center
-
Ephrata, Pennsylvania, Spojené státy, 17522
- Ephrata Cancer Center
-
Gettysburg, Pennsylvania, Spojené státy, 17325
- Adams Cancer Center
-
Hanover, Pennsylvania, Spojené státy, 17331
- WellSpan Medical Oncology and Hematology
-
Hazleton, Pennsylvania, Spojené státy, 18201
- Geisinger Medical Center-Cancer Center Hazleton
-
Jefferson Hills, Pennsylvania, Spojené státy, 15025
- Jefferson Hospital
-
Johnstown, Pennsylvania, Spojené státy, 15901
- UPMC-Johnstown/John P. Murtha Regional Cancer Center
-
Lancaster, Pennsylvania, Spojené státy, 17601
- Lancaster General Ann B Barshinger Cancer Institute
-
Lancaster, Pennsylvania, Spojené státy, 17602
- Lancaster General Hospital
-
Lebanon, Pennsylvania, Spojené státy, 17042
- Sechler Family Cancer Center
-
Monroeville, Pennsylvania, Spojené státy, 15146
- Forbes Hospital
-
Monroeville, Pennsylvania, Spojené státy, 15146
- UPMC Hillman Cancer Center - Monroeville
-
Philadelphia, Pennsylvania, Spojené státy, 19107
- Thomas Jefferson University Hospital
-
Pittsburgh, Pennsylvania, Spojené státy, 15224
- West Penn Hospital
-
Pittsburgh, Pennsylvania, Spojené státy, 15232
- UPMC Hillman Cancer Center
-
Pittsburgh, Pennsylvania, Spojené státy, 15213
- UPMC-Magee Womens Hospital
-
Pottsville, Pennsylvania, Spojené státy, 17901
- Geisinger Cancer Services-Pottsville
-
Scranton, Pennsylvania, Spojené státy, 18510
- Community Medical Center
-
West Reading, Pennsylvania, Spojené státy, 19611
- Reading Hospital
-
Wexford, Pennsylvania, Spojené státy, 15090
- Wexford Health and Wellness Pavilion
-
Wilkes-Barre, Pennsylvania, Spojené státy, 18711
- Geisinger Wyoming Valley/Henry Cancer Center
-
Willow Grove, Pennsylvania, Spojené státy, 19090
- Asplundh Cancer Pavilion
-
York, Pennsylvania, Spojené státy, 17403
- WellSpan Health-York Cancer Center
-
York, Pennsylvania, Spojené státy, 17403
- WellSpan Health-York Hospital
-
-
Rhode Island
-
Providence, Rhode Island, Spojené státy, 02905
- Women and Infants Hospital
-
-
South Carolina
-
Charleston, South Carolina, Spojené státy, 29425
- Medical University of South Carolina
-
Greenville, South Carolina, Spojené státy, 29605
- Prisma Health Cancer Institute - Faris
-
Greenville, South Carolina, Spojené státy, 29607
- Saint Francis Cancer Center
-
Greenville, South Carolina, Spojené státy, 29601
- Saint Francis Hospital
-
Seneca, South Carolina, Spojené státy, 29672
- Prisma Health Cancer Institute - Seneca
-
-
South Dakota
-
Rapid City, South Dakota, Spojené státy, 57701
- Rapid City Regional Hospital
-
Sioux Falls, South Dakota, Spojené státy, 57105
- Avera Cancer Institute
-
Sioux Falls, South Dakota, Spojené státy, 57104
- Sanford Cancer Center Oncology Clinic
-
-
Tennessee
-
Memphis, Tennessee, Spojené státy, 38120
- Baptist Memorial Hospital and Cancer Center-Memphis
-
Nashville, Tennessee, Spojené státy, 37232
- Vanderbilt University/Ingram Cancer Center
-
-
Texas
-
Dallas, Texas, Spojené státy, 75235
- Parkland Memorial Hospital
-
Dallas, Texas, Spojené státy, 75390
- UT Southwestern/Simmons Cancer Center-Dallas
-
Houston, Texas, Spojené státy, 77030
- Houston Methodist Hospital
-
Houston, Texas, Spojené státy, 77030
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
-
Houston, Texas, Spojené státy, 77070
- Methodist Willowbrook Hospital
-
Houston, Texas, Spojené státy, 77030
- Ben Taub General Hospital
-
Sugar Land, Texas, Spojené státy, 77479
- Houston Methodist Sugar Land Hospital
-
The Woodlands, Texas, Spojené státy, 77385
- Houston Methodist The Woodlands Hospital
-
-
Utah
-
Salt Lake City, Utah, Spojené státy, 84112
- Huntsman Cancer Institute/University of Utah
-
Salt Lake City, Utah, Spojené státy, 84106
- University of Utah Sugarhouse Health Center
-
-
Vermont
-
Burlington, Vermont, Spojené státy, 05401
- University of Vermont Medical Center
-
-
Virginia
-
Charlottesville, Virginia, Spojené státy, 22908
- University of Virginia Cancer Center
-
Richmond, Virginia, Spojené státy, 23298
- VCU Massey Comprehensive Cancer Center
-
-
Washington
-
Gig Harbor, Washington, Spojené státy, 98335
- MultiCare Gig Harbor Medical Park
-
Kennewick, Washington, Spojené státy, 99336
- Kadlec Clinic Hematology and Oncology
-
Puyallup, Washington, Spojené státy, 98372
- MultiCare Good Samaritan Hospital
-
Renton, Washington, Spojené státy, 98055
- Valley Medical Center
-
Seattle, Washington, Spojené státy, 98122
- Swedish Medical Center-First Hill
-
Tacoma, Washington, Spojené státy, 98405
- MultiCare Tacoma General Hospital
-
Vancouver, Washington, Spojené státy, 98686
- Legacy Salmon Creek Hospital
-
-
West Virginia
-
Charleston, West Virginia, Spojené státy, 25304
- Vandalia Health/CAMC Institute for Academic Medicine
-
Morgantown, West Virginia, Spojené státy, 26506
- West Virginia University Healthcare
-
Morgantown, West Virginia, Spojené státy, 26505
- Monongalia Hospital
-
-
Wisconsin
-
Burlington, Wisconsin, Spojené státy, 53105
- Aurora Cancer Care-Southern Lakes VLCC
-
Eau Claire, Wisconsin, Spojené státy, 54701
- Marshfield Medical Center-EC Cancer Center
-
Germantown, Wisconsin, Spojené státy, 53022
- Aurora Health Care Germantown Health Center
-
Grafton, Wisconsin, Spojené státy, 53024
- Aurora Cancer Care-Grafton
-
Green Bay, Wisconsin, Spojené státy, 54311
- Aurora BayCare Medical Center
-
Kenosha, Wisconsin, Spojené státy, 53142
- Aurora Cancer Care-Kenosha South
-
Madison, Wisconsin, Spojené státy, 53792
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Marinette, Wisconsin, Spojené státy, 54143
- Aurora Bay Area Medical Group-Marinette
-
Marshfield, Wisconsin, Spojené státy, 54449
- Marshfield Medical Center-Marshfield
-
Milwaukee, Wisconsin, Spojené státy, 53209
- Aurora Cancer Care-Milwaukee
-
Milwaukee, Wisconsin, Spojené státy, 53215
- Aurora Saint Luke's Medical Center
-
Milwaukee, Wisconsin, Spojené státy, 53233
- Aurora Sinai Medical Center
-
Minocqua, Wisconsin, Spojené státy, 54548
- Marshfield Medical Center - Minocqua
-
Oconomowoc, Wisconsin, Spojené státy, 53066
- ProHealth Oconomowoc Memorial Hospital
-
Oshkosh, Wisconsin, Spojené státy, 54904
- Vince Lombardi Cancer Clinic - Oshkosh
-
Racine, Wisconsin, Spojené státy, 53406
- Aurora Cancer Care-Racine
-
Rice Lake, Wisconsin, Spojené státy, 54868
- Marshfield Medical Center-Rice Lake
-
Sheboygan, Wisconsin, Spojené státy, 53081
- Vince Lombardi Cancer Clinic-Sheboygan
-
Stevens Point, Wisconsin, Spojené státy, 54482
- Marshfield Medical Center-River Region at Stevens Point
-
Summit, Wisconsin, Spojené státy, 53066
- Aurora Medical Center in Summit
-
Two Rivers, Wisconsin, Spojené státy, 54241
- Vince Lombardi Cancer Clinic-Two Rivers
-
Waukesha, Wisconsin, Spojené státy, 53188
- UW Cancer Center at ProHealth Care
-
Wauwatosa, Wisconsin, Spojené státy, 53226
- Aurora Cancer Care-Milwaukee West
-
West Allis, Wisconsin, Spojené státy, 53227
- Aurora West Allis Medical Center
-
Weston, Wisconsin, Spojené státy, 54476
- Marshfield Medical Center - Weston
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
-
Measurable stage III, measurable stage IVA, stage IVB (with or without measurable disease) or recurrent (with or without measurable disease) endometrial cancer.
-
Pathology report showing results of institutional MMR IHC testing.
-
Histologic confirmation of the original primary tumor is required (submission of pathology report(s) is required). Patients with the following histologic types are eligible: Endometrioid adenocarcinoma, serous adenocarcinoma, dedifferentiated/undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, adenocarcinoma not otherwise specified (N.O.S.).
-
Submission of tumor specimens for centralized MMR IHC testing is required after Step 1 and before Step 2 registration.
-
In patients with measurable disease, lesions will be defined and monitored by RECIST version (v) 1.1. Measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded). Each lesion must be >= 10 mm when measured by CT or magnetic resonance imaging (MRI). Lymph nodes must be >= 15 mm in short axis when measured by CT or MRI.
-
Patients may have received
- NO prior chemotherapy for treatment of endometrial cancer OR
- Prior adjuvant chemotherapy (e.g., paclitaxel/carboplatin alone or as a component of concurrent chemotherapy and radiation therapy [with or without cisplatin]) provided adjuvant chemotherapy was completed >= 12 months prior to STEP 2 registration.
-
Patients may have received prior radiation therapy for treatment of endometrial cancer. Prior radiation therapy may have included pelvic radiation therapy, extended field pelvic/para aortic radiation therapy, intravaginal brachytherapy, and/or palliative radiation therapy. All radiation therapy must be completed at least 4 weeks prior to STEP 2 registration.
-
Patients may have received prior hormonal therapy for treatment of endometrial cancer. All hormonal therapy must be discontinued at least three weeks prior to STEP 2 registration.
-
Interval or cytoreductive surgery, after start of treatment on this trial, and prior to documentation of disease progression, is NOT permitted.
-
Age >= 18.
-
Performance status of 0, 1 or 2.
-
Platelets >= 100,000/mcl.
-
Absolute neutrophil count (ANC) >= 1,500/mcl.
-
Creatinine =< 1.5 x institutional/laboratory upper limit of normal (ULN).
-
Total serum bilirubin level =< 1.5 x ULN (patients with known Gilbert's disease who have bilirubin level =< 3 x ULN may be enrolled).
-
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN.
-
Thyroid stimulating hormone (TSH) within normal limits. If TSH is not within normal range despite no symptoms of thyroid dysfunction, normal Free T4 level is required.
-
Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of Step 2 registration are eligible for this trial.
-
For patients of child bearing potential: negative urine or serum pregnancy test. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test is required.
-
Administration of study drugs (pembrolizumab [MK-3475], paclitaxel, carboplatin) may have an adverse effect on pregnancy and poses a risk to the human fetus, including embryo-lethality. Women of childbearing potential (WOCBP) must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) from at least 14 days prior to Step 2 registration (for oral contraceptives), during treatment, and for 120 days after the last dose of study medication. Should a woman become pregnant or suspect she is pregnant while she is participating in this study, she should inform her treating physician immediately. Patients will be considered of nonreproductive potential if they are either:
- Postmenopausal (defined as at least 12 months with no menses without an alternative medical cause; in women < 45 years of age, a high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy. In the absence of 12 months of amenorrhea, a single FSH measurement is insufficient); OR
- Have a hysterectomy and/or bilateral oophorectomy, bilateral salpingectomy or bilateral tubal ligation/occlusion, at least 6 weeks prior to Step 2 registration; OR
- Have a congenital or acquired condition that prevents childbearing.
-
Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.
-
The patient or a legally authorized representative must provide study-specific informed consent prior to study entry and, for patients treated in the United States (U.S.), authorization permitting release of personal health information.
Exclusion Criteria:
-
Patients with prior treatment with anti-PD-1, anti-PD-L1 or anti-CTLA-4 therapeutic antibody or other similar agents.
-
Patients who have a history of a severe hypersensitivity reaction to monoclonal antibody or pembrolizumab (MK-3475) and/or its excipients; and/or a severe hypersensitivity reaction to paclitaxel and/or carboplatin.
-
Patients who are currently participating and receiving cancer-directed study therapy or have participated in a study of an investigational agent and received cancer-directed study therapy within 4 weeks prior to Step 2 registration.
-
Patients who have a diagnosis of immunodeficiency or are receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to Step 2 registration.
- Patients who have received steroids as CT scan contrast premedication may be enrolled.
- The use of inhaled or topical corticosteroids is allowed.
- The use of mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowed.
- The use of physiologic doses of corticosteroids may be approved after consultation with the study chair.
-
Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression, and they have been off steroids for at least 4 weeks prior to Step 2 registration and remain clinically stable.
-
Patients with active autoimmune disease or history of autoimmune disease that might recur, which may affect vital organ function or require immune suppressive treatment including systemic corticosteroids. This includes, but is not limited to, patients with a history of immune related neurologic disease, multiple sclerosis, autoimmune (demyelinating) neuropathy, Guillain-Barre syndrome, myasthenia gravis; systemic autoimmune disease such as systemic lupus erythematosus (SLE), connective tissue diseases, scleroderma, inflammatory bowel disease (IBD), Crohn's, ulcerative colitis, hepatitis; and patients with a history of toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome, or phospholipid syndrome because of the risk of recurrence or exacerbation of disease.
-
Patients with vitiligo, endocrine deficiencies including type I diabetes mellitus, thyroiditis managed with replacement hormones including physiologic corticosteroids are eligible.
-
Patients with rheumatoid arthritis and other arthropathies, Sjogren's syndrome and psoriasis controlled with topical medication and patients with positive serology, such as antinuclear antibodies (ANA), anti-thyroid antibodies should be evaluated for the presence of target organ involvement and potential need for systemic treatment but should otherwise be eligible.
-
Patients who have a history of (non-infectious) pneumonitis that required steroids, or current pneumonitis.
-
Uncontrolled intercurrent illness including, but not limited to: ongoing or active infection (except for uncomplicated urinary tract infection), interstitial lung disease or active, non-infectious pneumonitis, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
-
Known clinically significant liver disease, including active viral, alcoholic, or other hepatitis; and cirrhosis.
- For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.
- Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.
-
Pregnant or lactating patients.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Čtyřnásobek
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Aktivní komparátor: Arm I (placebo, paclitaxel, carboplatin)
COMBINATION PHASE: Patients receive placebo IV over 30 minutes on day 1 of each cycle, paclitaxel IV over 3 hours on day 1 of each cycle, and carboplatin IV over 30-60 minutes on day 1 of each cycle. Treatment repeats every 3 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with SD or PR who still have measurable disease may continue treatment for up to a total of 10 cycles (if deemed necessary by the treating physician) in the absence of disease progression or unacceptable toxicity. MAINTENANCE PHASE: Patients receive placebo IV over 30 minutes on day 1 of each cycle. Treatment repeats every 6 weeks for up to 14 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan throughout the study. On February 6, 2023, all patient treatment assignments were unblinded. Patients randomized to Arm 1 will not receive additional placebo infusions. |
Given IV
Ostatní jména:
Given IV
Ostatní jména:
Ancillary studies
Ostatní jména:
Given IV Ancillary studies Undergo CT scan
Ostatní jména:
|
|
Experimentální: Arm II (pembrolizumab, paclitaxel, carboplatin)
COMBINATION PHASE: Patients receive pembrolizumab IV over 30 minutes on day 1 of each cycle, paclitaxel IV over 3 hours on day 1 of each cycle, and carboplatin IV over 30 minutes on day 1 of each cycle. Treatment repeats every 3 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with SD or PR who still have measurable disease may continue treatment for up to a total of 10 cycles (if deemed necessary by the treating physician) in the absence of disease progression or unacceptable toxicity. MAINTENANCE PHASE: Patients receive pembrolizumab IV over 30-60 minutes on day 1 of each cycle. Treatment repeats every 6 weeks for up to 14 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan throughout the study. |
Given IV
Ostatní jména:
Given IV
Ostatní jména:
Ancillary studies
Ostatní jména:
Ancillary studies Given IV
Ostatní jména:
Undergo CT scan
Ostatní jména:
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Progression-free Survival (PFS)
Časové okno: Duration of time from study entry to time of progression per RECIST criteria or death due to any cause, whichever occurs first. The interquartile range for follow-up was (6.37 months, 30.62 months). The maximum for follow-up was 37.85 months.
|
Progression free survival (PFS) Note: For arm 2 (dMMR Cohort), the point estimate and the upper limit of the confidence interval are not able to be estimated due to insufficient events. |
Duration of time from study entry to time of progression per RECIST criteria or death due to any cause, whichever occurs first. The interquartile range for follow-up was (6.37 months, 30.62 months). The maximum for follow-up was 37.85 months.
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Adverse Events With Grade 3 (or Higher)
Časové okno: For the adverse event time frame, the interquartile range was (0.79 months, 3.42 months); the maximum was 28.39 months.
|
Assessed by Common Terminology Criteria for Adverse Events (CTCAE V5.0). The endpoint is the count of participants with an adverse event of grade 3 (or higher) by treatment group. |
For the adverse event time frame, the interquartile range was (0.79 months, 3.42 months); the maximum was 28.39 months.
|
|
Objective Tumor Response
Časové okno: For the time frame for tumor response, the interquartile range was (2.27 months, 8.66 months) and the maximum was 36.37 months.
|
Assessed by Response Evaluation Criteria for Solid Tumors (RECIST) 1.1. |
For the time frame for tumor response, the interquartile range was (2.27 months, 8.66 months) and the maximum was 36.37 months.
|
|
Duration of Objective Response
Časové okno: For the duration of objective response, the interquartile range is (4.24 months, 7.92 months); the maximum is 28.68 months.
|
The time difference between the dates of first response and first progression; patients who do not progress are considered censored. Note: for Arm 2 (dMMR Cohort), the upper limit of the confidence interval is not able to be estimated due to an insufficient number of events. |
For the duration of objective response, the interquartile range is (4.24 months, 7.92 months); the maximum is 28.68 months.
|
|
Overall Survival (OS)
Časové okno: Time from study entry to time of death or the date of last contact, assessed up to 5 years
|
Overall Survival (OS). This endpoint will be assessed by Kaplan-Meier. |
Time from study entry to time of death or the date of last contact, assessed up to 5 years
|
|
Quality of Life (QoL) in pMMR Patients Only
Časové okno: 0-54 weeks from start of treatment
|
QoL are collected in pMMR patients only and measured with the Function Assessment of Cancer Therapy -Endometrial Trial Outcome Index (FACT En-TOI). The FACT-En TOI scores range 0 - 120 with a larger score suggesting better or favorable state of QOL. |
0-54 weeks from start of treatment
|
|
Concordance Between Institutional Mismatch Repair (MMR) Immunohistochemistry (IHC) Testing and Centralized MMR IHC
Časové okno: IHC testing values (for both central and institutional) were collected at baseline.
|
Concordance between institutional MMR IHC testing and centralized MMR IHC. The concordance of institutional MMR IHC testing and centralized MMR IHC will be characterized by agreement statistics including the kappa statistic (e.g. Cohen's kappa coefficient). |
IHC testing values (for both central and institutional) were collected at baseline.
|
Další výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Incidence of Pembrolizumab Treatment and Self-reported Neurotoxicity
Časové okno: 0-54 weeks from start of treatment
|
Patient-reported neurotoxicity will be measured with FACT/GOG-Ntx subscale (short form). |
0-54 weeks from start of treatment
|
|
Effect of Pembrolizumab on PFS and OS by Program Death Ligand 1 (PD-L1) IHC
Časové okno: 5 years
|
Will assess the effect of pembrolizumab on PFS and OS by PD-L1 (combined positive score [CPS]) within proficient MMR (pMMR) and deficient MMR (dMMR) populations. The effectiveness of pembrolizumab will be compared by PD-L1 status (CPS). A formal test will be conducted by examining the interaction term between pembrolizumab treatment (yes or no) with PD-L1 status. The association between PD-L1 CPS status and MMR IHC status will be assessed with odds ratios. A test may be conducted with a Fisher's Exact Test, and confidence intervals will be provided. |
5 years
|
|
Association Between PD-L1 IHC and MMR Status
Časové okno: 5 years
|
Measures of association between PD-L1 IHC (CPS) and MMR IHC status. The concordance of institutional MMR IHC testing and centralized MMR IHC will be characterized by agreement statistics such as kappa statistics (e.g. Cohen's kappa coefficient). |
5 years
|
Spolupracovníci a vyšetřovatelé
Sponzor
Vyšetřovatelé
- Vrchní vyšetřovatel: Ramez N Eskander, NRG Oncology
Publikace a užitečné odkazy
Obecné publikace
- Morton M, Marcu I, Levine M, Cosgrove C, Backes F, O'Malley D, Chambers L. Evaluation of Efficacy and Adverse Events After Second Immunotherapy Exposure in Endometrial and Cervical Carcinoma. Obstet Gynecol. 2023 Aug 1;142(2):360-363. doi: 10.1097/AOG.0000000000005243. Epub 2023 Jul 5.
- Eskander RN, Sill MW, Beffa L, Moore RG, Hope JM, Musa FB, Mannel RS, Shahin MS, Cantuaria GH, Girda E, Lokich E, Kavecansky J, Leath CA 3rd, Gien LT, Hinchcliff EM, Lele SB, Landrum LM, Backes F, O'Cearbhaill RE, Baghdadi TA, Hill EK, Thaker PH, John VS, Welch S, Fader AN, Powell MA, Aghajanian C. Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial. Nat Med. 2025 May;31(5):1539-1546. doi: 10.1038/s41591-025-03566-1. Epub 2025 Mar 5.
- Eskander RN, Sill MW, Beffa L, Moore RG, Hope JM, Musa FB, Mannel R, Shahin MS, Cantuaria GH, Girda E, Mathews C, Kavecansky J, Leath CA 3rd, Gien LT, Hinchcliff EM, Lele SB, Landrum LM, Backes F, O'Cearbhaill RE, Al Baghdadi T, Hill EK, Thaker PH, John VS, Welch S, Fader AN, Powell MA, Aghajanian C. Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer. N Engl J Med. 2023 Jun 8;388(23):2159-2170. doi: 10.1056/NEJMoa2302312. Epub 2023 Mar 27.
- Bogani G, Monk BJ, Powell MA, Westin SN, Slomovitz B, Moore KN, Eskander RN, Raspagliesi F, Barretina-Ginesta MP, Colombo N, Mirza MR. Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancer. Ann Oncol. 2024 May;35(5):414-428. doi: 10.1016/j.annonc.2024.02.006. Epub 2024 Feb 29.
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Aktuální)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
- Urogenitální onemocnění
- Onemocnění genitálií
- Urogenitální novotvary
- Novotvary podle místa
- Novotvary
- Ženské urogenitální onemocnění
- Ženské urogenitální onemocnění a těhotenské komplikace
- Novotvary podle histologického typu
- Onemocnění dělohy
- Onemocnění pohlavních orgánů, ženy
- Genitální novotvary, ženy
- Novotvary dělohy
- Sarkom
- Novotvary, pojivové a měkké tkáně
- Novotvary, komplexní a smíšené
- Novotvary endometria
- Karcinosarkom
- Organické chemikálie
- Uhlovodíky
- Cykloparafiny
- Uhlovodíky, alicyklické
- Uhlovodíky, cyklické
- Terpeny
- Koordinační komplexy
- Taxoidy
- Cyclodecanes
- Diterpeny
- Ekonomika a organizace zdravotní péče
- Ekonomika
- Karboplatina
- Paklitaxel
- Pembrolizumab
- Daně
Další identifikační čísla studie
- NCI-2019-02186
- U10CA180868 (Grant/smlouva NIH USA)
- NCI-2019-02186 (Identifikátor registru: CTRP (Clinical Trial Reporting Program))
- NRG-GY018 (Jiný identifikátor: CTEP)
- NRG-GY018 (Jiný identifikátor: NRG Oncology)
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
produkt vyrobený a vyvážený z USA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .